Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences' President and CEO, Derek J. Maetzold, sold over 30,000 shares of common stock in pre-scheduled transactions.

Summary

• Derek J. Maetzold, President & CEO and Director of Castle Biosciences Inc., sold a total of 30,779 shares of common stock.
• These sales were executed under a Rule 10b5-1 trading plan adopted on December 3, 2025.
• On March 13, 2026, 13,204 shares were sold at a weighted-average price of $25.447 per share.
• On March 16, 2026, 17,449 shares were sold at a weighted-average price of $25.964 per share.
• Also on March 16, 2026, an additional 126 shares were sold at a price of $26.68 per share.
• Following these transactions, Mr. Maetzold directly owns 40,779 shares and indirectly owns 253,736 shares through various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were pre-scheduled under a Rule 10b5-1 plan, which reduces the negative signaling typically associated with insider selling.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the transactions were not based on new, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, reduces the direct equity stake of a key executive, which can sometimes be perceived negatively by the market.
• A significant number of shares (30,779) were sold.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common occurrence for executives managing personal finances or diversifying portfolios. In the biotechnology sector, executive stock sales are often scrutinized for potential signals regarding future company performance or clinical trial outcomes, though a 10b5-1 plan typically mitigates such interpretations.

Comparison to Industry Standards

• Sales under a Rule 10b5-1 plan are a standard practice for executives to sell shares without being accused of trading on inside information.
• For example, executives at companies like Amgen or Gilead Sciences frequently utilize 10b5-1 plans for pre-scheduled stock dispositions, making these transactions routine rather than indicative of specific company distress or exceptional performance.
• The volume of shares sold by Mr. Maetzold is not unusually high compared to similar executive sales at companies of comparable market capitalization in the biotech industry.

Related Party Transactions

• The filing details indirect beneficial ownership through various trusts (e.g., The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, DJM Grantor Retained Annuity Trusts), which are related parties to the reporting person. However, the reported transactions are sales of common stock by the reporting person, not transactions with these trusts.

Stakeholder Impact

• Shareholders might perceive a slight negative signal from executive share sales, though the 10b5-1 plan mitigates this.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

The insider sales were conducted under a pre-arranged 10b5-1 plan, which typically indicates a planned financial move rather than a reaction to new material information. While insider selling can sometimes be a negative signal, the pre-planned nature makes it less impactful. Without additional financial or operational updates, a 'hold' recommendation is appropriate as this filing alone does not provide a strong catalyst for a change in investment thesis.

Keywords

Castle Biosciences, CSTL, Insider Trading, Form 4, Derek Maetzold, Stock Sale, 10b5-1 Plan, Biotechnology, Healthcare, CEO